South Plainfield, NJ -- December 27, 2012 -- GENEWIZ, Inc., leading global genomic service provider, is highlighted as a top contract research organization (CRO) with entrepreneurial leadership by BioBAY in the Nature Biotechnology and Nature Reviews Drug Discovery spotlight 'Report on Biotech in China.'
With operations in Beijing and Suzhou, China, GENEWIZ offers researchers the advantages of working with a global service provider, while maintaining local access to support. Home to the GENEWIZ China headquarters, BioBAY is "a biopharmaceutical ecosystem promoting innovation and expansion."
"BioBAY offers us a supportive environment conducive to company growth and service expansion," commented Dr. Ping Yang, Vice President of Gene Synthesis and Molecular Biology. "Here, we successfully achieved the prestigious ISO 9001:2008 Quality Management System certification, demonstrating our constant commitment to delivering the highest quality gene synthesis and genomic services."
To learn more about GENEWIZ’s global presence, as featured in Nature Biotechnology andNature Reviews Drug Discovery Biopharma Dealmakers, please click here.
About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GxP/CLIA regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; San Diego, CA; Washington, DC Metro; Research Triangle Park, NC; and Seattle, WA. International locations include Beijing, China; Suzhou, China; and London, United Kingdom.